RRMM 患者 CAR-T 细胞治疗后细胞免疫的长期分析

Chimeric antigen receptor T (CAR-T) cell therapy exhibits remarkable efficacy against refractory or relapsed multiple myeloma (RRMM); however, the immune deficiency following CAR-Ts infusion has not been well studied. In this study, 126 patients who achieved remission post-CAR-Ts infusion were evaluated for cellular immunity. Following lymphodepletion (LD) chemotherapy, the absolute lymphocyte count (ALC) and absolute counts of lymphocyte subsets were significantly lower than baseline at D0. Grade 3 lymphopenia occurred in 99% of patients within the first 30 days, with most being resolved by 180 days.

The median CD4 + T-cell count was consistently below baseline and the lower limit of normal (LLN) levels at follow-up. Conversely, the median CD8 + T-cell count returned to the baseline and LLN levels by D30. The median B-cell count remained lower than baseline level at D60 and returned to baseline and LLN levels at D180.

In the first 30 days, 27 (21. 4%) patients had 29 infections, with the majority being mild to moderate in severity (21/29; 72. 4%). After day 30, 44 (34. 9%) patients had 56 infections, including 20 severe infections. One patient died from bacteremia at 3. 8 months post-CAR-Ts infusion.

In conclusion, most patients with RRMM experienced cellular immune deficiency caused by LD chemotherapy and CAR-Ts infusion. The ALC and most lymphocyte subsets gradually recovered after day 30 of CAR-Ts infusion, except for CD4 + T cells. Some patients experience prolonged CD4 + T-cell immunosuppression without severe infection.